Camrelizumab Combined With Apatinib Mesylate

Inclusion Criteria: 1. Age: ≥18 years old, male or female; 2. ECOG score is 0\~2; 3. Patients with solid tumors confirmed by pathology or histology; 4. At least one measurable lesion (according to RECIST V 1.1); 5. For patients who have failed first-line or second-line treatment or who cannot tolerate standard treatment regimens for solid tumors. 6. Estimated survival ≥3 months; 7. Patients who have used immunosuppressants or antiangiogenic drugs in the past are not excluded; 8. For women who have not undergone menopause or surgical sterilization, agree to abstain from sex or use an effective contraceptive method during treatment and for at least 7 months after the last dose given in study treatment; 9. Researchers think they can benefit; 10. Voluntarily participate in the study and sign the informed consent; Exclusion Criteria: 1. Pregnant or lactating women; 2. Except patients with contraindications to camrelizumab and/or apatinib mesylate, that is, those allergic to camrelizumab and its excipients; Allergic to apatinib mesylate should be prohibited; It should be contraindication for patients with active bleeding, ulcers, intestinal perforation, intestinal obstruction, hypertension beyond drug control within 30 days after major surgery, class III-IV cardiac insufficiency (NYHA standard), and severe hepatic or renal insufficiency (Class 4). 3. Those deemed unsuitable for inclusion by doctors; 4. The researchers determined there was a high risk that the tumor would invade important blood vessels and cause fatal hemorrhages during the follow-up study